Valneva SE: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Vivalis SA Issues FY 2013 Revenue Guidance
Vivalis SA announced that it expects its revenue to increase for full year 2013 compared to full year 2012 as a result of its commercial strategy. The Company reported full year 2012 revenue of EUR 3.43 million.
Latest Developments for Valneva SE
- Valneva SE announces approval and launch in South America of second veterinary vaccine produced in EB66 cell line
- Valneva SE issues FY 2014 revenue guidance
- Valneva SE Confirms FY 2013 Revenue Guidance in Line with Analysts' Estimates
- Valneva SE Provides Update on Phase II/III Interim Analysis of Its Pseudomonas Aeruginosa Vaccine Candidate
Latest Key Developments in Biotechnology
- Genera Biosystems Ltd announces FDA advisory committee recommends HPV test as primary cervical cancer screening tool
- Virax Holdings Ltd to acquire Pathway Oncology Pty Ltd
- Omeros Corp prices $35.0 million public offering of common stock
- Navidea Biopharmaceuticals Inc announces presentation of Lymphoseek three-year recurrence and survival outcomes after Sentinel Lymph Node Biopsy in Patients with Breast Cancer and Melanoma
- Share this
- Digg this